Alzheimer’s is the only condition among the top ten cause of death with no known treatment to cure or even slow the progression of disease. Lot of money have been spent to find a cure for Alzheimer’s with 99% failure rate .Most big pharma companies such as Roche , Eli Lilly, AstraZeneca Plc and Johnson and Johnson have earlier abandoned all trials testing their experimental drugs based on amyloid beta even those in stage III due to lack of any encouraging results.
I have been following the Alzheimer’s space for a long time since someone very close was diagnosed and have seen and understood the impact of it. As more and more of our families get old and get lonely back home there is need to care more and find a cure for Alzheimer’s . In India we normally refer to it as memory loss and call it dementia in general and is attributed to aging and we don't really understand the impact of Alzheimer’s on our elders. I was happy when I saw that awareness being created by showing about Alzheimer’s is the latest 'Josh' Uri movie.
One of the companies that is working and has shown some progress is a small Stockholm based company called BioArctic , I was surprized last June when I saw a small company go up 700% from 22 to 172 in less than a weeks time after there were positive results in their Phase IIb. The full 18 month analysis of the 856 patient on BAN2401 in Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain. I had read about this company when an investment company called Öresund had bought stocks sometime back.
Last week one of big pharma companies Biogen has pulled the plug on its trials for aducanumab, which was a drug similar as BioArctic amyloid targetting BAN2401 and that made Biogen loose 30% of their stock value and wiping out close to 18 Billion is marketcap considering 10-12 billion runrate on thier potential Alzheimer’s drug . The outcome indirectly had an major impact on BioArctic aswell which lost close to 30% of its value as its Alzheimer’s drug was similar to Biogen.
BioArctic CEO came out with the clarification that even though both are antibodies within A-beta, but all antibodies have some differences and BAN2401 is the only project that has shown really strong phase 2b- results with clinical effect in a large study and will continue with the phase 3 trails.
After reading more on the differences I decided to take a smallbite and bought 25 BioArctic for SEK 75 last week and I already own Biogen .
Another company in Stockholm that is in to Alzheimer’s is AlzeCure Pharma that has 5 candidates that are yet to start their Phase I.
A kind request PLEASE PLEASE pass the below link to the article about Alzheimer’s that was publish in Fortune Magazine in February 19 to anyone you know who have parents or grandparents nearing 70+ , pls do it as a favor to me . Ask them to read as it may help them to understand and to manage dementia in aging population.
http://fortune.com/longform/alzheimers-disease-cure-breakthrough/
I have been following the Alzheimer’s space for a long time since someone very close was diagnosed and have seen and understood the impact of it. As more and more of our families get old and get lonely back home there is need to care more and find a cure for Alzheimer’s . In India we normally refer to it as memory loss and call it dementia in general and is attributed to aging and we don't really understand the impact of Alzheimer’s on our elders. I was happy when I saw that awareness being created by showing about Alzheimer’s is the latest 'Josh' Uri movie.
One of the companies that is working and has shown some progress is a small Stockholm based company called BioArctic , I was surprized last June when I saw a small company go up 700% from 22 to 172 in less than a weeks time after there were positive results in their Phase IIb. The full 18 month analysis of the 856 patient on BAN2401 in Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain. I had read about this company when an investment company called Öresund had bought stocks sometime back.
Last week one of big pharma companies Biogen has pulled the plug on its trials for aducanumab, which was a drug similar as BioArctic amyloid targetting BAN2401 and that made Biogen loose 30% of their stock value and wiping out close to 18 Billion is marketcap considering 10-12 billion runrate on thier potential Alzheimer’s drug . The outcome indirectly had an major impact on BioArctic aswell which lost close to 30% of its value as its Alzheimer’s drug was similar to Biogen.
BioArctic CEO came out with the clarification that even though both are antibodies within A-beta, but all antibodies have some differences and BAN2401 is the only project that has shown really strong phase 2b- results with clinical effect in a large study and will continue with the phase 3 trails.
After reading more on the differences I decided to take a smallbite and bought 25 BioArctic for SEK 75 last week and I already own Biogen .
Another company in Stockholm that is in to Alzheimer’s is AlzeCure Pharma that has 5 candidates that are yet to start their Phase I.
A kind request PLEASE PLEASE pass the below link to the article about Alzheimer’s that was publish in Fortune Magazine in February 19 to anyone you know who have parents or grandparents nearing 70+ , pls do it as a favor to me . Ask them to read as it may help them to understand and to manage dementia in aging population.
http://fortune.com/longform/alzheimers-disease-cure-breakthrough/
No comments:
Post a Comment